Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock

Key Points

• Alpha Tau Medical CFO Raphi Levy sold 17,730 shares for $248,220 at an average price of $14.00, reducing his direct holdings by 16.43% to 90,180 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
• DRTS shares traded at $13.64, near their 12-month high of $14.40, with the 50-day and 200-day moving averages at $11.68 and $9.23, respectively. The company recently reported a quarterly loss of $0.50 per share, missing the consensus estimate of a $0.14 loss.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating from eight analysts and a $12.80 target price, although ratings range from Buy to Sell.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 17,730 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.00, for a total transaction of $248,220.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company's stock, valued at approximately $1,262,520. The trade was a 16.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Price Performance

Shares of DRTS traded down $0.63 during trading hours on Wednesday, hitting $13.64. 278,117 shares of the stock were exchanged, compared to its average volume of 591,397. The stock's 50-day moving average price is $11.68 and its two-hundred day moving average price is $9.23. Alpha Tau Medical Ltd. has a 12-month low of $3.00 and a 12-month high of $14.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -13.12 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.36). The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.14 million. Research analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Benchmark restated a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. LADENBURG THALM/SH SH boosted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, May 12th. Zacks Research upgraded Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a report on Monday, August 3rd. Finally, Piper Sandler raised their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a "neutral" rating in a research note on Tuesday, May 19th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.80.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Trifecta Capital Advisors LLC acquired a new stake in Alpha Tau Medical during the fourth quarter worth $48,000. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical in the 3rd quarter valued at $62,000. Bank of America Corp DE grew its holdings in shares of Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock worth $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN increased its position in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Everhart Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical during the 2nd quarter worth about $126,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source